Multiple Organ Dysfunction Syndrome in Children With Sepsis: Role of Genetic Factors

Seminars in Nephrology

Volumn 28, Issue 5, 2008, Pages 499-509

  Liangos, Orfeas ^a   Jaber, Bertrand L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute kidney injury; dysfunction syndrome; Genetic risk markers; multiple organ; sepsis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CATALASE; CD32 ANTIGEN; COMPLEMENT FACTOR H; CREATININE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MANNOSE BINDING LECTIN 2; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPERDIN; PROSTANOID; PROTEINASE; RANTES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ACUTE KIDNEY FAILURE; ALLELE; AMINO ACID SUBSTITUTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BACTEREMIA; BLOOD CLOTTING DISORDER; BLOOD LEVEL; CAPILLARY LEAK SYNDROME; CHILDHOOD DISEASE; CHROMOSOME SUBSTITUTION; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DNA FLANKING REGION; DNA SEQUENCE; EXON; FATIGUE; FIBRINOLYSIS; FLU LIKE SYNDROME; GENE DELETION; GENE INSERTION; GENE THERAPY; GENETIC CODE; GENETIC EPIDEMIOLOGY; GENETIC LINKAGE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOTYPE; HALF LIFE TIME; HEADACHE; HEREDITY; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOMODULATION; INFLAMMATION; INTRON; KIDNEY INJURY; MENINGOCOCCOSIS; MULTIPLE ORGAN FAILURE; NAUSEA; NEISSERIA MENINGITIDIS; NEUTROPHIL; NONHUMAN; OPSONIZATION; OUTCOME ASSESSMENT; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT SELECTION; PERFUSION; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; RENAL REPLACEMENT THERAPY; RNA PROCESSING; SEPSIS; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; SYNTHESIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TARGET ORGAN; TISSUE INJURY; TRANSCRIPTION INITIATION; TRANSLATION INITIATION; VASCULAR ENDOTHELIUM; VASODILATATION; VOMITING;

BIOLOGICAL MARKERS; CHILD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE ORGAN FAILURE; POLYMORPHISM, GENETIC; PROGNOSIS; SEPSIS;

EID: 51249092145     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2008.05.011     Document Type: Article

References (108)

1. Castellanos-Ortega A., Delgado-Rodriguez M., Llorca J., Sanchez Buron P., Mencia Bartolome S., Soult Rubio A., et al. A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems. Intensive Care Med 28 (2002) 341-351
2. Bagshaw S.M., and Bellomo R. Fluid resuscitation and the septic kidney. Curr Opin Crit Care 12 (2006) 527-530
3. Licari E., Calzavacca P., Ronco C., and Bellomo R. Fluid resuscitation and the septic kidney: the evidence. Contrib Nephrol 156 (2007) 167-177
4. Nussbaum R., McInnes R., and Willard H. Genetic variation in individuals: mutation and polymorphism. Thompson & Thompson genetics in medicine (2001), WB Saunders Company, Philadelphia 79-94
5. van Deventer S. Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 26 Suppl 1 (2000) S98-S1002
6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 (1992) 864-874
7. Jaber B.L., and Pereira B.J.G. Inflammatory mediators in sepsis: rationale for extracorporeal therapies. Am J Kidney Dis 28 (1996) S35-S49
8. Pinsky M.R.V.J., Deviere J., Alegre M., Kahn R.J., and Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103 (1993) 565-575
9. Casey L.C.B.R., and Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119 (1993) 771-778
10. Scumpia P.O., and Moldawer L.L. Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Crit Care Med 33 (2005) S468-S471
11. Song M., and Kellum J.A. Interleukin-6. Crit Care Med 33 (2005) S463-S465
12. Dinarello C.A. Interleukin-1beta. Crit Care Med 33 (2005) S460-S462
13. Koch T. Origin and mediators involved in sepsis and the systemic inflammatory response syndrome. Kidney Int 53 Suppl 64 (1998) S66-S69
14. Opal S., and DePalo V. Anti-inflammatory cytokines. Chest 117 (2000) 1162-1172
15. Tabardel Y., Duchateau J., Schmartz D., Marecaux G., Shahla M., Barvais L., et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 119 (1996) 76-80
16. Fillinger M.P., Rassias A.J., Guyre P.M., Sanders J.H., Beach M., Pahl J., et al. Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J Cardiothorac Vasc Anesth 16 (2002) 163-169
17. Wilson A.G., de Vries N., Pociot F., di Giovine F.S., van der Putte L.B., and Duff G.W. An allelic polymorphism within the human tumor necrosis factor-alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177 (1993) 557-560
18. Morse H., Olomolaiye O., Wood N., Keen L., and Bidwell J. Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 11 (1999) 789-795
19. Abraham L.J., and Kroeger K.M. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 66 (1999) 562-566
20. Wilson A.G.S.J., McDowell T.L., McDewitt H.O., and Duff G.W. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A 94 (1997) 3195-3199
21. Kroeger K.M., Carville K.S., and Abraham L.J. The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 34 (1997) 391-399
22. Warzocha K., Ribeiro P., and Bienvenu J. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91 (1998) 3574-3581
23. Louis E., Franchimont D., and Piron A. Tumor necrosis factor gene polymorphism influences TNF-alpha production in lipopolysaccharide-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113 (1998) 401-406
24. Mira J.-P., Cariou A., Grall F., Delclaux C., Losser M.-R., Heshmati F., et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 282 (1999) 561-568
25. Tang G.J., Huang S.L., Yien H.W., Chen W.S., Chi C.W., Wu C.W., et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 28 (2000) 2733-2736
26. Weitkamp J.H., Stuber F., and Bartmann P. Pilot study assessing TNF gene polymorphism as a prognostic marker for disease progression in neonates with sepsis. Infection 28 (2000) 92-96
27. Wunderink R.G., Waterer G.W., Cantor R.M., and Quasney M.W. Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest 121 (2002) 87S
28. Nadel S., Newport M.J., Booy R., and Levin M. Variation in the tumor necrosis factor-α promoter region may be associated with death from meningococcal disease. J Infect Dis 174 (1996) 878-880
29. Mcguire W., Hill A.V., Allsopp C.E., Greenwood B.M., and Kwiatkowski D. Variation of the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 371 (1994) 508-510
30. Cabrera M., Shaw M.A., and Sharples C. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 182 (1995) 1259-1264
31. Jaber B., Rao M., Guo D., Balakrishnan V., Perianayagam M., Freeman R., et al. Cytokine promoter gene polymorphisms and mortality in acute renal failure. Cytokine 25 (2004) 212-219
32. Treszl A., Toth-Heyn P., Kocsis I., Nobilis A., Schuler A., Tulassay T., et al. Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol 17 (2002) 713-717
33. Bokodi G., Treszl A., Derzbach L., Balogh A., and Vasarhelyi B. The association of the carrier state of the tumor necrosis factor-alpha (TNFalpha) -308A allele with the duration of oxygen supplementation in preterm neonates. Eur Cytokine Netw 16 (2005) 78-80
34. Abraham L., Du D., Zahedi K., Dawkins R., and Whitehead A. Haplotypic polymorphisms of the TNFB gene. Immunogenetics 33 (1991) 50-53
35. Pociot F., Molvig J., Wogensen L., Worsaae H., Dalboge H., Baek L., et al. A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scand J Immunol 33 (1991) 37-49
36. Stuber F., Petersen M., Bokelmann F., and Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24 (1996) 381-384
37. Majetschak M., Flohe S., Obertacke U., Schroder J., Staubach K., Nast-Kolb D., et al. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230 (1999) 207-214
38. Heesen M., Kunz D., Bachmann-Mennenga B., Merk H., and Bloemeke B. Linkage disequilibrium between tumor necrosis factor (TNF)-alpha-308 G/A promoter and TNF-beta NcoI polymorphisms: association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med 31 (2003) 211-214
39. Read R., Cannings C., Naylor S., Timms J., Maheswaran R., Borrow R., et al. Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 138 (2003) 534-541
40. Virta M., Hurme M., and Helminen M. Increased frequency of interleukin-1beta (-511) allele 2 in febrile seizures. Pediatr Neurol 26 (2002) 192-195
41. Berger P., McConnell J., Nunn M., Kornman K., Sorrell J., Stephenson K., et al. C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine 17 (2002) 171-174
42. Santtila S., Savinainen K., and Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 47 (1998) 195-198
43. Andus T., Daig R., Vogl D., Aschenbrenner E., Lock G., Hollerbach S., et al. Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut 41 (1997) 651-657
44. Tountas N., Casini-Raggi V., Yang H., Di Giovine F., Vecchi M., Kam L., et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117 (1999) 806-813
45. Fang X., Schroder S., Hoeft A., and Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 27 (1999) 1330-1334
46. Ma P., Chen D., Pan J., and Du B. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 30 (2002) 1046-1050
47. Barton B. IL-6: insights into novel biological activities. Clin Immunol Immunopathol 85 (1997) 16-20
48. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102 (1998) 1369-1376
49. Fernandez-Real J.M., Broch M., Vendrell J., Richart C., and Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85 (2000) 1331-1333
50. Schluter B., Raufhake C., Erren M., Schotte H., Kipp F., Rust S., et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 30 (2002) 32-37
51. Baier R.J., Loggins J., and Yanamandra K. IL-10, IL-6 and CD14 polymorphisms and sepsis outcome in ventilated very low birth weight infants. BMC Med 4 (2006) 10
52. Crawley E., Kay R., Sillibourne J., Patel P., Hutchinson I., and Woo P. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42 (1999) 1101-1108
53. van der Pol W.L.H.T., Vidarsson G., van der Linden M.W., Jansen M.D., Keijsers V., de Straat F.G., et al. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 184 (2001) 1548-1555
54. Gallagher P., Lowe G., Fitzgerald T., Bella A., Greene C., McElvaney N., et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 58 (2003) 154-156
55. Jaber B., Liangos O., Pereira B., and Balakrishnan V. Polymorphism of immuno-modulatory cytokine genes: implications in acute renal failure. Blood Purif 22 (2004) 101-111
56. Yanamandra K., Boggs P., Loggins J., and Baier R.J. Interleukin-10 -1082 G/A polymorphism and risk of death or bronchopulmonary dysplasia in ventilated very low birth weight infants. Pediatr Pulmonol 39 (2005) 426-432
57. Hoebee B., Bont L., Rietveld E., van Oosten M., Hodemaekers H.M., Nagelkerke N.J., et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis 189 (2004) 239-247
58. Segerer S., and Alpers C.E. Chemokines and chemokine receptors in renal pathology. Curr Opin Nephrol Hypertens 12 (2003) 243-249
59. Segerer S., and Nelson P.J. Chemokines in renal diseases. Sci World J 5 (2005) 835-844
60. Miura M., Fu X., Zhang Q.W., Remick D.G., and Fairchild R.L. Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am J Pathol 159 (2001) 2137-2145
61. Maier S., Emmanuilidis K., Entleutner M., Zantl N., Werner M., Pfeffer K., et al. Massive chemokine transcription in acute renal failure due to polymicrobial sepsis. Shock 14 (2000) 187-192
62. Jiang Z., Okhuysen P., Guo D., He R., King T., DuPont H., et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea polymorphism in the IL-8 promotor region at position -251. J Infect Dis 188 (2003) 506-511
63. Hull J., Thomson A., and Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55 (2000) 1023-1027
64. Kruger B., Schroppel B., Ashkan R., Marder B., Zulke C., Murphy B., et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13 (2002) 2585-2589
65. Amoli M.M., Thomson W., Hajeer A.H., Calvino M.C., Garcia-Porrua C., Ollier W.E., et al. Interleukin 8 gene polymorphism is associated with increased risk of nephritis in cutaneous vasculitis. J Rheumatol 29 (2002) 2367-2370
66. Amanatidou V., Sourvinos G., Apostolakis S., Neonaki P., Tsilimigaki A., Krambovitis E., et al. RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. Pediatr Infect Dis J 27 (2008) 38-42
67. Macdonald J., Galley H., and Webster N. Oxidative stress and gene expression in sepsis. Br J Anaesth 90 (2003) 221-232
68. Hoy A., Leininger-Muller B., Kutter D., Siest G., and Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 40 (2002) 2-8
69. Ursini F., Maiorino M., Brigelius-Flohe R., Aumann K., Roveri A., Schomburg D., et al. Diversity of glutathione peroxidases. Methods Enzymol 252 (1995) 38-53
70. Flohe L. Glutathione peroxidase. Basic Life Sci 49 (1988) 663-668
71. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med 27 (1999) 916-921
72. Forsberg L., de Faire U., and Morgenstern R. Oxidative stress, human genetic variation, and disease. Arch Biochem Biophys 389 (2001) 84-93
73. Fukai T., Folz R., Landmesser U., and Harrison D. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res 55 (2002) 239-249
74. Baliga R., Ueda N., Walker P., and Shah S. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31 (1999) 971-997
75. Druml W., Schwarzenhofer M., Apsner R., and Horl W. Fat-soluble vitamins in patients with acute renal failure. Miner Electrolyte Metab 24 (1998) 220-226
76. Metnitz P., Fischer M., Bartens C., Steltzer H., Lang T., and Druml W. Impact of acute renal failure on antioxidant status in multiple organ failure. Acta Anaesthesiol Scand 44 (2000) 236-240
77. Balakrishnan V., Blumberg J., Pereira B., and Jaber B. Antioxidant and oxidative stress indices in dialysis-dependent acute renal failure. Blood Purif 21 (2003) 213-219
78. Inoue N., Kawashima S., Kanazawa K., Yamada S., Akita H., and Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22phox gene in patients with coronary artery disease. Circulation 97 (1998) 135-137
79. Guzik T., West N., Black E., McDonald D., Ratnatunga C., Pillai R., et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102 (2000) 1744-1747
80. Hodgkinson A.D., Millward B.A., and Demaine A.G. Association of the p22phox component of NAD(P)H oxidase with susceptibility to diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 26 (2003) 3111-3115
81. Forsberg L., Lyrenas L., de Faire U., and Morgenstern R. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 30 (2001) 500-505
82. Nadif R., Mintz M., Jedlicka A., Bertrand J.P., Kleeberger S.R., and Kauffmann F. Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli. Free Radic Res 39 (2005) 1345-1350
83. Perianayagam M., Liangos O., Kolyada A., Wald R., MacKinnon R., Li L., et al. NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol 18 (2007) 255-263
84. Platonov A.E., Shipulin G.A., Vershinina I.V., Dankert J., van de Winkel J.G., and Kuijper E.J. Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 27 (1998) 746-750
85. Domingo P., Muniz-Diaz E., Baraldes M.A., Arilla M., Barquet N., Pericas R., et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 112 (2002) 19-25
86. Domingo P., Muniz-Diaz E., Baraldes M.A., Arilla M., Barquet N., Pericas R., et al. Relevance of genetically determined host factors to the prognosis of meningococcal disease. Eur J Clin Microbiol Infect Dis 23 (2004) 634-637
87. Smith I., Vedeler C., and Halstensen A. FcgammaRIIa and FcgammaRIIIb polymorphisms were not associated with meningococcal disease in Western Norway. Epidemiol Infect 130 (2003) 193-199
88. Bathum L., Hansen H., Teisner B., Koch C., Garred P., Rasmussen K., et al. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol 43 (2006) 473-479
89. Haralambous E., Dolly S.O., Hibberd M.L., Litt D.J., Udalova I.A., O'Dwyer C., et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 38 (2006) 764-771
90. Hermans P.W., Hibberd M.L., Booy R., Daramola O., Hazelzet J.A., de Groot R., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354 (1999) 556-560
91. Westendorp R.G., Hottenga J.J., and Slagboom P.E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354 (1999) 561-563
92. Geishofer G., Binder A., Muller M., Zohrer B., Resch B., Muller W., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 164 (2005) 486-490
93. Haralambous E., Hibberd M.L., Hermans P.W., Ninis N., Nadel S., and Levin M. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 31 (2003) 2788-2793
94. Binder A., Endler G., Muller M., Mannhalter C., and Zenz W. 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost 5 (2007) 2049-2054
95. Kremer Hovinga J.A., Franco R.F., Zago M.A., Ten Cate H., Westendorp R.G., and Reitsma P.H. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J Thromb Haemost 2 (2004) 54-57
96. Read R., Camp N., di Giovine F., Borrow R., Kaczmarski E., Chaudhary A., et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 182 (2000) 1557-1560
97. Endler G., Marculescu R., Starkl P., Binder A., Geishofer G., Muller M., et al. Polymorphisms in the interleukin-1 gene cluster in children and young adults with systemic meningococcemia. Clin Chem 52 (2006) 511-514
98. Harding D., Baines P.B., Brull D., Vassiliou V., Ellis I., Hart A., et al. Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med 165 (2002) 1103-1106
99. Balding J., Healy C.M., Livingstone W.J., White B., Mynett-Johnson L., Cafferkey M., et al. Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease?. Genes Immun 4 (2003) 533-540
100. Ridker P., and Stampfer M. Assessment of genetic markers for coronary thrombosis: promise and precaution. Lancet 353 (1999) 687-688
101. Newman T.B., Browner W.S., and Hulley S.B. Enhancing causal inference in observational studies. In: Hulley S.B., and Cummings S.R. (Eds). Designing clinical research (1988), Williams & Wilkins, Baltimore 98-109
102. Nabel E. Genomic medicine: cardiovascular disease. N Engl J Med 349 (2003) 60-72
103. Ioannidis J.P., and Trikalinos T.A. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J Clin Epidemiol 58 (2005) 543-549
104. Rosenthal N., and Schwartz R. In search of perverse polymorphisms. N Engl J Med 338 (1998) 122-124
105. Star R.A. Treatment of acute renal failure. Kidney Int 54 (1998) 1817-1831
106. Molitoris B.A. Transitioning to therapy in ischemic acute renal failure. J Am Soc Nephrol 14 (2003) 265-267
107. Jaber B.L., Liangos O., Pereira B.J., and Balakrishnan V.S. Polymorphism of immunomodulatory cytokine genes: implications in acute renal failure. Blood Purif 22 (2004) 101-111
108. Aidoo M., McElroy P.D., Kolczak M.S., Terlouw D.J., ter Kuile F.O., Nahlen B., et al. Tumor necrosis factor-alpha promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. Genet Epidemiol 21 (2001) 201-211